Population Analysis of Anidulafungin in Infants to Older Adults With Confirmed or Suspected Invasive Candidiasis.
Administration, Intravenous
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Anidulafungin
/ administration & dosage
Antifungal Agents
/ administration & dosage
Candidiasis, Invasive
/ diagnosis
Child
Child, Preschool
Clinical Trials as Topic
Dose-Response Relationship, Drug
Drug Dosage Calculations
Drug Monitoring
Humans
Infant
Infant, Newborn
Male
Middle Aged
Models, Biological
Treatment Outcome
Young Adult
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
02
12
2019
accepted:
28
02
2020
pubmed:
20
3
2020
medline:
25
5
2021
entrez:
20
3
2020
Statut:
ppublish
Résumé
In a pooled population analysis, we investigated the pharmacokinetics of i.v. anidulafungin in four studies across a full range of adult and pediatric ages in patients with confirmed, suspected, or at high risk of invasive candidiasis (IC). Relationships between anidulafungin exposure and key efficacy end points (global response of success and all-cause mortality) and safety end points (all-cause hepatic or gastrointestinal adverse events) in all patients and separately in pediatric patients and the appropriate dosing regimen for IC treatment in pediatric patients were evaluated. Pediatric patients received a 3.0 mg/kg (maximum 200 mg) i.v. loading dose and 1.5 mg/kg (maximum 100 mg) daily thereafter. Adults received a 200 mg i.v. loading dose and 100 mg daily thereafter. Estimated systemic anidulafungin exposures were similar across age groups (neonates to adults) at the weight-based doses studied in pediatric patients. No clear associations were identified between anidulafungin exposure and efficacy or safety end points.
Identifiants
pubmed: 32189334
doi: 10.1002/cpt.1831
pmc: PMC7485140
doi:
Substances chimiques
Antifungal Agents
0
Anidulafungin
9HLM53094I
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
316-325Informations de copyright
© 2020 Pfizer Pte Ltd. Clinical Pharmacology & Therapeutics Published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Antimicrob Agents Chemother. 2009 Mar;53(3):1149-56
pubmed: 19029327
Clin Microbiol Infect. 2012 Dec;18 Suppl 7:53-67
pubmed: 23137137
Clin Pharmacokinet. 2016 Oct;55(10):1289-1294
pubmed: 27142114
N Engl J Med. 2015 Oct 8;373(15):1445-56
pubmed: 26444731
J Clin Pharmacol. 2007 Apr;47(4):461-70
pubmed: 17389555
Antimicrob Agents Chemother. 2012 Feb;56(2):708-14
pubmed: 22123680
J Pediatr. 2013 Oct;163(4):961-7.e3
pubmed: 23726546
Clin Microbiol Infect. 2012 Dec;18 Suppl 7:19-37
pubmed: 23137135
Clin Pharmacol Ther. 2011 May;89(5):702-7
pubmed: 21412233
Antimicrob Agents Chemother. 2018 Jun 26;62(7):
pubmed: 29712664
J Clin Pharmacol. 2007 Mar;47(3):305-14
pubmed: 17322142
Pediatrics. 2003 Sep;112(3 Pt 1):634-40
pubmed: 12949295
Antimicrob Agents Chemother. 2013 Jan;57(1):466-74
pubmed: 23129052
Clin Microbiol Infect. 2012 Dec;18 Suppl 7:38-52
pubmed: 23137136
Pediatrics. 2006 Jan;117(1):84-92
pubmed: 16396864
Clin Infect Dis. 2005 Nov 1;41(9):1232-9
pubmed: 16206095
Pediatr Infect Dis J. 2019 Mar;38(3):275-279
pubmed: 30418357
Pediatr Infect Dis J. 2014 Feb;33(2):e40-4
pubmed: 23995591
Clin Infect Dis. 2016 Feb 15;62(4):e1-50
pubmed: 26679628
J Clin Pharmacol. 2004 Jun;44(6):590-8
pubmed: 15145966
Antimicrob Agents Chemother. 2006 Feb;50(2):632-8
pubmed: 16436720
Pediatr Infect Dis J. 2020 Apr;39(4):305-309
pubmed: 32032174
Clin Infect Dis. 2003 Sep 1;37(5):634-43
pubmed: 12942393